The Board of Directors met in Turin, Italy on September, 2006, and several important decisions were made. Candidate to host the World Conference in 2011 were identified and IASLC is now undergoing detailed negotiations. IASLC Fellowships have increased in numbers and several fellowships are available for application this fall (see below). A new initiative that may impact our external activities is the contract with a worldwide public relations company (Spectrum Science, Washington DC), which will promote IASLC-activities and policies in the future. Another new initiative is that IASLC has added to the web site (www.iaslc.org) a new section to announce new career development possibilities. We encourage IASLC members to use this IASLC website to announce new positions relevant to the IASLC community.
Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter
IASLC Statement on Screening:
International Association for the Study of Lung Cancer (IASLC) Statement on Lung Cancer Screening with spiral CT:
- The IASLC is the largest International profession society whose sole mission is to reduce lung cancer mortality through prevention, research, education and improved therapy.
- Lung cancer is the most common cause of cancer death in the world accounting for up to 29% of all cancer deaths in developed countries.
- The 5 year survival rates for lung cancer patients are less than 15% lagging far behind that of other cancers. The low survival rates reflect the level of effective screening modalities and the inability of systemic therapies to cure advanced stage patients.
- Reduction in tobacco smoking reduces lung cancer mortality. The IASLC tobacco policy can be found at www.iaslc.org.
- Smokers and others at high risk for lung cancer should consult their physicians for appropriate prevention and early detection procedures.
- The 5 year survival rate for the most favorable stage (IA) approximates 70% in historical series using outdated staging evaluations.
- The IASLC has created a new database of >100,000 patients gathered worldwide, who have undergone more modern staging evaluation and will release data in 2007 to update current staging classification and survival rates.
- Effective screening procedures such as spiral CT have the potential to detect early lung cancers that could reduce lung cancer mortality.
- Single arm trials of spiral CT screening show high detection rates for small pulmonary nodules (most of which are benign), high rates of detection of Stage I lung cancer, and high survival rates for the screen detected stage I cancers.
- The high false positive rates, the potential morbidity and mortality from work-up of benign lesions, the high costs and the potential for over-diagnosis are unresolved issues.
- Prospective randomized clinical trials are the only known way to determine if spiral CT screening will reduce lung cancer mortality. Fortunately, such trials with over 100,000 subjects worldwide have been conducted with 50,000 of these on the National Lung screening Trial (NLST) sponsored by the NCI in the USA. The results of these trials are eagerly awaited and will likely determine future screening recommendations.
- Lung cancer research worldwide is underfunded and increased funding would likely hasten reductions in lung cancer mortality.
Letter to Editor of NEJM
To the Editor:
Research published in the October 26, 2006 New England Journal of Medicine supporting precautionary screening to detect early lung cancer has generated excitement among some physicians and cancer patient advocates who view it as evidence that it saves lives and that such testing should become routine. Widespread media coverage of the study (“Study Supports Early Screening for Lung Cancer,” The Wall Street Journal, October 26, 2006) has fueled the notion that regular spiral CT screening for lung cancer should be akin to mammograms or colonoscopies, tools used to detect early breast and colon cancer.
While the results of the study are encouraging, it’s important to note that it did not include a comparison group to clearly show that the CT screening saved lives. This key
factor is lost in the enthusiasm for moving CT screening into the mainstream. CT screenings have high false-positive rates, and there are serious risks associated with surgery to remove a non-cancerous lesion in the lung. Until we have more definitive results from the ongoing gold-standard, randomized, controlled trial by the National Cancer Institute, the International Association for the Study of Lung Cancer does not recommend that this screening act as standard clinical practice.
Lung cancer is the leading cause of cancer deaths, and more research is needed to find ways to better diagnose and treat it. Increased funding for lung cancer research would hasten the work to definitively demonstrate the value of technology such as CT, and reduce the impact of this devastating disease.
Paul Bunn, M.D., Executive Director
International Association for the Study of Lung Cancer
IASLC/CRPF Prevention/Translational Research Fellowship Award and IASLC Lung Cancer Fellowship Award/Young Investigators Award:
The IASLC is proud to announce a continuation and expansion of the IASLC Fellowship and Young Investigators Programs.
Overall there are 17 potential awards for two years each. There are 4 awards in prevention and translational lung cancer research that are jointly sponsored with the Cancer Research and Prevention Foundation (CRPF) through educational grants from Eli Lilly (3) and Bristol-Myers Squibb (1). There are 13 unrestricted awards in any field of lung cancer research supported by educational grants from GlaxoSmithKline (3), Sanofi-Aventis (3), AstraZeneca (3), Pfizer (1), Eli Lilly (1), OSI (1) and EMD Pharmaceuticals (1).
This year 8 new unrestricted awards of $40,000 each year for 2 years are available for competition.
We are now requesting application for these Fellowships and Young Investigator awards to be awarded in 2007. The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer. The applications will be evaluated by a Scientific Review Panel; the deadline for submission of the application is January 5, 2007. A decision on applications will be reached by March 2007.
Application forms can be found at the website: www.iaslc.org
Please e-mail you application to: pia.Hirsch@uchsc.edu latest January 5, 2007
Journal of Thoracic Oncology (JTO), Supplement on Bronchioalveolar Carcinoma, November 2006:
Fred R. Hirsch, MD, PhD; David H. Johnson, MD; Vincent A. Miller, MD
BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models.
David C. Christiani, MD; William Pao, MD, PhD; James C. DeMartini, DVM, PhD; R Ilona Linnoila, MD; Alvin M. Malkinson, PhD; Amir Onn, MD; Katerina A. Politi, PhD; Michael Sharp, MD; Kwok- Kim, MD, PhD
Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma.
Marie Wislez, MD; David G. Beer, PhD; Ignacio Wistuba, MD; Jacques Cadranel, MD, PhD; Nagahiro Saijo, MD; Bruce E. Johnson, MD
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria.
William D. Travis, MD; Kavita Garg, MD; Wilbur A. Franklin, MD; Ignacio I. Wistuba, MD; Bradley Sabloff, MD; Masayuki Noguchi, MD; Ryutaro Kakinuma, MD; Maureen Zakowski, MD; Michelle Ginsberg, MD; Robert Padera, MD; Francine Jacobson, MD; Bruce E. Johnson, MD; Fred Hirsch, MD; Elizabeth Brambilla, MD; Douglas B. Flieder, MD; Kim R. Geisinger, MD; Frederik Thunnissen, MD; Keith Kerr, MD; David Yankelevitz, MD; Teri J. Franks, MD; Jeffrey R. Galvin, MD; Douglas W. Henderson, MD; Andrew G. Nicholson, MD; Philip S. Hasleton, MD; Victor Roggli, MD; Ming-Sound Tsao, MD; Federico Cappuzzo, MD; Madeline Vazquez, MD
Radiographic Imaging of Bronchioloalveolar Carcinoma: Screening, Patterns of Presentation and Response Assessment.
David R. Gandara, MD; Denise Aberle, MD; Derick Lau, MD, PhD; James Jett, MD; Tim Akhurst, MD, PhD; James Mulshine, MD; Christine Berg, MD; Edward F. Patz Jr, MD
Surgery for Bronchioloalveolar Carcinoma and "Very Early" Adenocarcinoma: An Evolving Standard of Care?
Valerie W. Rusch, MD; Ryosuke Tsuchiya, MD, PhD; Masahiro Tsuboi, MD; Harvey I. Pass, MD; Dominique Grunenwald, MD; Peter Goldstraw, FRCS
Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma.
Mark G. Kris, MD; Giuseppe Giaccone, MD; Angela Davies, MD; Masahiro Fukuoka, MD; David H. Garfield, MD; Jacek Jassem, MD; Elisabeth A. Quoix, MD; Alan B. Sandler, MD; Giorgio V. Scagliotti, MD; Jan P. Van Meerbeeck, MD, PhD; Howard West, MD
The Cancer Genome Atlas Project:
The National Cancer Institute/National Human Genome Research Institute, USA have announced that they will include lung adenocarcinomas as one of the three cancer tissue types in their first-ever pilot project to catalogue genetic changes in human cancers. The goal is to sequence the genome of the disease. This pilot project is expected to take three years.
For more information hhttp://cancergenome.nih.gov/index.asp
The Stacey Scott International Lung Cancer Registry for preneoplasia:
Initiated by Roswell Park Cancer Institute and made possible through a private donation, an international multi institutional registry of preneoplasia has been established. The goal of the registry is to collect histopathological and clinical information from high-risk subjects, who have undergone fluorescence bronchoscopy as a part of various clinical protocols including chemoprevention studies. The goal is to obtain information of a large scale that can be used to identify histopathological and clinical risk factors for development of lung cancer.
Further information, please visit www.stacey.registry.org
Eric Thunnissen, MD, an active participant in the IASLC Pathology Panel, has recently moved from Nijmegen, Holland to a position at the free University in Amsterdam. E-mail: firstname.lastname@example.org
Dominique H. Grunenwald, MD, Professor in Thoracic and Cardiovascular Surgery, has accepted a new position as Head of the Department of Thoracic Surgery, in Hopital Tenon, University of Paris, France. E-mail : email@example.com
Thierry LeChevalier, MD, Director of International Relations, the French National Cancer Institute and Professor at Institute Gustave Roussy has accepted a position as Vice President Europe and Scientific Advisor, Oncology in GlaxoSmithKline, London, UK. Dr. LeChevalier is a long standing active member of IASLC and was awarded IASLC Scientific Award in 2005. E-mail: firstname.lastname@example.org
Bevacizumab FDA approved:
The US Food and Drug Administration has recently approved Bevacizumab (Avastin®, Genentech/Roche) in combination with paclitaxel and carboplatin as a first line treatment of advanced/metastatic non-squamous non-small cell lung cancer. The approval is based on the results from the Eastern Cooperative Oncology Group (ECOG) study E 4599, which showed a significant increase in survival for patients receiving Avastin + chemotherapy versus chemotherapy alone. The final publication is expected in New England Journal of Medicine, December 2006.
IASLC welcome 29 new members:
Vinod Ganju MBBS, FRACP
Nezih Ozdemir MD, PhD
David Fenton MD, FRCP(C)
David Blowers PhD
Patricia Schaffner MD
Waun Ki Hong MD
Biruta Witte MD
Ross Bremner MD
Thomas D'Amato MD, PhD
Thomas D'Amico MD
Balazs Dome MD, PhD
David Follette MD
Laurie E. Gaspar MD, MBA
Anna Spreafico MD
Paul Keall PhD
Kenneth Kesler MD
John Nemunaitis MD
Kyung Soo Lee MD, PhD
Jeffrey Port MD
Kwan Ho Cho MD
Ramesh Rengan MD, PhD
David Spigel MD
Ad Verhagen MD
J.W.A. Oosterhuis MD, PhD
Michael J. Weyant MD
Wouter Jacobs MD
Atasha Asmat MB BCh
December 1-3, 2006 2nd Asia-Pacific Lung Cancer Conference Place: Guangzhou, China Contact: Dr. Yi-Long Wu Email: email@example.com
January 23-26, 2007 BTOG Meeting Place: Dublin, Ireland Contact: Ken O'Byrne, MD Email: firstname.lastname@example.org
February 16-17, 2007 Pisa Lung Cancer Conference Contact: Andrea Ardizzoni Email: email@example.com
February 22-24, 2007 IASLC Targeted Therapies for the Treatment of Lung Cancer Place: Santa Monica, CA USA Chairs: Paul A. Bunn, Jr., David Johnson and Roy Herbst For more information, please contact Pia Hirsch at firstname.lastname@example.org Please visit www.thecbce.com
September 2-6, 2007 The 12th World Conference on Lung Cancer - IASLC Place: Seoul, Korea Contact: Conference Secretariat E-mail: email@example.com For more information, please visit www.2007worldlungcancer.org
November 3-6, 2007 Turkish Thoracic Society Place: Istanbul, Turkey Contact: Muzaffer Metintas, MD Email: firstname.lastname@example.org
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
September 14 2015 - March 12 2016Multiple Locations Around the World
September 18 2015Phoenix, AZ
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer - New York, New YorkOctober 2 2015New York, New York